Else Nutrition Holdings Inc (BABY) 시세

Dumbest investors I've ever seen. Now off 24% today alone. Insiders clearly dumping.

Right but she would thereby admit defeat and I think she would not be able to do so.
Alternatively, finding a solid mass marketing professional and supporting him blindly (financing, planning, executing) could still save the company. I however again believe her ego would not accept that also.

seems as though the only salvation is finding a buyer

Soon to be a sub penny stock if our CEO keeps looking at it with her incredible incompetence (I almost have no doubt she will do so). I've been around stock markets for decades but never saw any executive that incompetent and stubborn. When I bought it initially (2019-12-13 BUY 1800 0,380 684,00 $ 9,95 $ 693,95) $) I really tought I had found a golden opportunity. Fortunately I thereafer traded somewhat accumulating shares an saving cash but it is absolutely incredible to withness that level of stupididy blowing up such an opportunity. Ho ... You win some, you lose some.

Agree 100%.

pual, "The woman is a disaster."
CORRECT, pps tells the story in no uncertain terms.

The woman is a disaster. She doesn't have a clue relative to what managing a MASS MARKETING OPERATION represents. She is a lab-rat, only concern by product. She operates in a mass marketing business but think marketing (an investment) is an expense to cut. More incompetent than that, you lead yourself to bancrupcy.
A few abstract from her NR:
- managing expenses.
- despite a very modest marketing budget.
- additional major US retailer.
- our products would be available in over 900 new US large grocery stores
- ongoing product innovations
- upcoming launch of our Adult RTD product,
- broaden our offerings
"To support our growth, we are in active discussions regarding non-dilutive bridge funding, and a long-term credit line’’.
Weren't my shares wortthless I would sell them.
‘’Concurrently, we've implemented strategic cost-saving measures aimed at improving our margins in future quarters.’’

Else Nutrition Reports 2024 Third Quarter Financial Results and Provides Business Update
7:45 AM ET 11/14/24 | Dow Jones

Else Nutrition Reports 2024 Third Quarter Financial Results and Provides Business Update

Canada NewsWire

VANCOUVER, BC, Nov. 14, 2024

Conference call to be held today at 10:00 AM Eastern Time

VANCOUVER, BC, Nov. 14, 2024 /CNW/ - ELSE NUTRITION HOLDINGS INC. (TSX: BABY) (OTCQX: BABYF) (FSE: 0YL.F) ("Else" or the "Company"), today reported financial results for the third quarter ended September 30, 2024. The financial statements and MD&A are available on SEDAR under the Company's profile.

Hamutal Yitzhak, CEO of Else Nutrition, commented, "We are making steady progress executing our growth strategy, while carefully managing expenses. We achieved a 5% year-over-year revenue increase in Q3 2024, despite a very modest marketing budget. Our ability to achieve these results demonstrates the growing consumer appetite for our products and our expanding retail presence."

"We are continuing to gain traction with retailers across North America, including our recent pilot program with Costco -- one of the largest North American wholesale retailers. We believe this could lead to distribution across more than 100 of their locations in Canada as a first step with the potential to expand throughout the US. This expansion represents a substantial opportunity to reach new consumers and build our brand. We are also in the process of finalizing the expanded availability of our kids RTD products with an additional major US retailer. Once finalized, our products would be available in over 900 new US large grocery stores, further enhancing our market reach. Additionally, we are proud of our ongoing product innovations, including the upcoming launch of our Adult RTD product, with the first commercial production scheduled for later this year. This is a key milestone as we broaden our offerings to meet the demand for convenient, healthy whole food, minimally processed and easy to digest, plant-based nutrition."

"To support our growth, we are in active discussions regarding non-dilutive bridge funding, and a long-term credit line that will enable us to ramp up our marketing efforts, optimize our capital structure, and drive our long-term growth strategy. Concurrently, we've implemented strategic cost-saving measures aimed at improving our margins in future quarters. We believe these operational improvements, combined with innovative product launches and an expanding retail presence, are positioning us for long-term financial success."

"Looking forward, we believe as we continue to execute on our financial strategy, it will enable us o expand our retail footprint, increase brand visibility, and continue to develop high-demand plant-based products. Our commitment to providing healthy, sustainable nutrition options places us at the forefront of the plant-based nutrition market, and we are excited about the opportunities that lie ahead."

2024 Third Quarter Financial Results

All figures are in CAD unless otherwise indicated.
-- Revenue for Q3 2024 increased approximately 5% to $1.8 million compared
to $1.71 million for the same period last year.

-- Operating expenses for Q3 2024 was $3.6 million compared to $3.5 million
in Q3 2023.

-- Cash balance as of September 30, 2024, was $0.9 million (including
restricted cash).

Conference Call

Else Nutrition management plans to host a business update conference call at 10:00 a.m. Eastern Time on November 14, 2024, to discuss the Company's financial results for the 2024 third quarter ended September 30, 2024, as well as the Company's corporate progress and other developments.

The conference call will be available via telephone by dialing toll free 1-877-704-4453 for U.S. callers or +1-201-389-0920 for international callers. A webcast of the call may be accessed at https://viavid.webcasts.com/starthere.jsp?ei=1696583&tp_key=1ad8612838 or on the Investor Relations section of the Company's website at https://investors.elsenutrition.com/.

A webcast replay will be available on the Investor Relations section of the Company's website (https://investors.elsenutrition.com/), through November 14, 2025. A telephone replay of the call will be available approximately three hours following the call, through November 21, 2024, and can be accessed by dialing 1-844-512-2921 for U.S. callers or +1-412-317-6671 for international callers and entering conference ID: 13750029.

To delve deeper into Else Nutrition's offerings and its revolutionary approach to kids' nutrition, visit www.elsenutrition.com

About Else Nutrition Holdings Inc.

Else Nutrition Holdings Inc. (TSX: BABY, OTCQX: BABYF, FSE: 0YL) is a food and nutrition company in the international expansion stage focused on developing innovative, clean, and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy formula is a clean-ingredient alternative to dairy-based formulas. Since launching its Plant-Based Complete Nutrition for Toddlers, made of whole foods, almonds, buckwheat, and tapioca, the brand has received thousands of powerful testimonials and reviews from parents, gained national retailer support, and achieved rapid sales growth.

Awards and Recognition:
-- "2017 Best Health and Diet Solutions" award at Milan's Global Food
Innovation Summit

-- #1 Best Seller on Amazon in the Fall of 2020 in the New Baby & Toddler
Formula Category

-- "Best Dairy Alternative" Award 2021 at World Plant-Based Expo

-- Nexty Award Finalist at Expo West 2022 in the Plant-Based lifestyle
category

-- During September 2022, Else Super Cereal reached the #1 Best Seller in
Baby Cereal across all brands on Amazon

-- In May 2024 Else Nutrition's Ready-to-Drink Kids Vanilla Shake Named
Among the Best in Family-Friendly Products by the Prestigious Mom's
Choice Awards(R)

TSX

Neither the TSX nor its regulation services provider (as that term is defined in the policies of the TSX) accept responsibility for the adequacy or accuracy of this release.

You can buy all the worthless patents and trademarks you want virtually free on eBay. Try it using the link below! Start your own junk penny stock.

Of course the better ones are almost expired...with only a few days left in them. Maybe an idiot or two might fall for it.

https://www.ebay.com/b/Patents-Trademarks-for-Sale/

pual, I wouldn't be surprised if the patents are owned by individual's, NOT the company.

VANCOUVER, BC, Nov. 6, 2024 /PRNewswire/ - ELSE NUTRITION HOLDINGS INC. (TSX: BABY) (OTCQX: BABYF) (FSE: 0YL.F) ("Else" or the "Company"), today announced that it plans to host a business update conference call at 10:00 a.m. Eastern Time on November 14, 2024 to discuss the Company's financial results for the 2024 third quarter ended September 30, 2024, as well as the Company's corporate progress and other developments.

If she has any smarts left, she tries to sell out the outfit but with current market value the pressure to give it for negligeable amount up would be great. However, I suspect the market value reflect the incompetence of our CEO but, taking her out of the picture gives our product line, patents and rights, a much greater value, In any case is our CEO dumb enough to not understand her stuborness is going to sink the boat sooner than later?

usually there is a PR indicating the next quarter report. All quiet from HQ.
PPS acting like belly up.

I wonder if our dreaming CEO finally figured out she has to sell out before she and we have to write off our investment?

I wonder if our dreaming CEO finally figured out she has to sell out before she and we have to write off our investment?

Someone is buying heavy. Look at the capitulation

A buyer steps up to bat @ .03.
$0.030.00 (0.00%)
Bid x Size
$0.03 x 2,024,987
Ask x Size
$0.0403 x 10,000
Real Time Equity Quote: Oct 14, 2024, 9:30 AM ET

there is no submission - FDA does not approve infant formula - they just set basic requirements

Anyone knows where we stand relative to our submission(s) to the FDA?

This is either a RS or trips before year end

Could be but I think she finances herself by increasing the number of O\S

How about a current honest value on The liabilities? The Debt? $Thousands? $Millions ???????? More?

Without an audit, I'd assume the numbers are really ugly

Our incompetent CEO is in panic and to stupid to look for help from a business type person. She enjoys a board made of scientifics discussing scientific subjects. for more than 3 years she did nothing to try to understand why the value of her company went down the drain. What a crazy dreamer !!!

Why no recent audits??? How hard would it be to put a current honest value on almonds, buckwheat and tapioca?

"When was the last time BABYF released audited numbers?"

Another way to do it. Good luck.

pual,
I've increased (at these current low prices)with intention of taking losses by year end.
Just selling on FIFO basis should provide the losses you desire.

I hope our CEO has now figured out that developing new products and\or adding shelves where to store our inventories is not really the objectives she should pursue.
I start to believe that if she doesn’t sell out her company and register rights we will have to write off our investment and include our loss as a tax deduction. At current price, I may sell out by year end, take my capital loss as a tax deduction (in Canada and Quebec) and buy back, just in case … who knows.

FDA approval has been waited for for almost 2 years and now the taste is another issue. Add that to the leadership of an incompetent CEO who doesn't know how to address these issues. As any incompetent business person facing such issues, our CEO think that cutting the expenses is a solution ... when it is generally another problem ... What a mess!

The whole "problem" could also be that their products taste like crap. Bought a container of their complete shake mix a few years ago and the only way my grandson would drink it is if I also put in a banana, regular milk and a few other ingredients. Defeats the purpose of paying a premium price for a plant-based mix. Never finished it so there's no way I was going to order it again. I'm really glad I sold all my shares (except 5000 in a forgotten account) about two years ago.

The whole "problem" could also be that their products taste like crap. Bought a container of their complete shake mix a few years ago and the only way my grandson would drink it is if I also put in a banana, regular milk and a few other ingredients. Defeats the purpose of paying a premium price for a plant-based mix. Never finished it so there's no way I was going to order it again. I'm really glad I sold all my shares (except 5000 in a forgotten account) about two years ago.

So..
How does the FDA oversee the safety and nutritional quality of infant formula??
Infant formula is a food that may be the sole source of nutrition for infants (i.e., children up to 12 months of age) as an alternative to human milk. The FDA regulatory requirements address, among other issues, the safety, nutritional adequacy, packaging, and labeling of these products. The FDA does not approve infant formulas; however, infant formula manufacturers must notify the agency before marketing a new formula. The FDA’s highly trained staff review these notifications to make sure new formulas meet federal nutrition, labeling, and other requirements. If a product does not meet applicable requirements, the formula may be deemed adulterated, misbranded, or both, and the FDA has the authority to take enforcement action. For example, the FDA can require a mandatory recall of product if the agency determines that an adulterated or misbranded infant formula presents a risk to human health.

Among the requirements for infant formulas, the FDA specifies 30 nutrients that must be included in infant formulas. There are minimum amounts for all 30 nutrients and maximum amounts for 10 nutrients. In addition, any ingredient used in infant formula must be safe and suitable for such use. Additionally, sanitary controls are required by law to prevent contamination and other safety problems from occurring. For example, manufacturers must establish a system of controls designed to ensure that infant formula does not become adulterated due to the presence of microorganisms in the formula or in the processing environment. Further, the FDA regulations set forth certain testing requirements of finished product for Salmonella and Cronobacter. FDA regulations also require that the water the companies use to manufacture formulas meets safety standards set by the U.S. Environmental Protection Agency.

The FDA has specific requirements for labeling infant formulas. Information that is most helpful for caregivers of infants includes directions for preparation and use, and a pictogram showing the major steps for preparing infant formula, a “use by” date.

The FDA inspects facilities that manufacture infant formulas annually and carefully trains its investigators to ensure that every infant formula inspection is robust, thorough, and focused on the most critical aspects of the infant formula manufacturing process.

All Infant formula products sold in the U.S., whether produced domestically or imported, must meet all U.S. requirements, including those for safety and nutritional adequacy. Caregivers should use caution when ordering imported products online or from third party distributors because some of these products have not undergone FDA's rigorous premarket review process and do not meet U.S. requirements for safety or nutritional adequacy.

....

When was the last time BABYF released audited numbers?

The whole problem is MARKETING (Our CEO thinks it's a useless EXPENSE) and therefore dismal revenues.
People do not know about us nor do they about our offerings.
Our CEO only talk to shareholders and the topics (except for mandatory filings) always relates to additional products she developped and shelves she added. That means additional costs. We have more and more products sitting on shelves (inventories) and more and more shelves to put them on.
Bottom line:
- minimal revenues (she doesn't know how to grow,
- growing expenses she tries to reduce (she doesn't know the difference between ''expense'' and ''investment''). She believe marketing to be an expense.

JP, ET is around $4.00, but I guess $50 would be ok if you but 100K.

not convs but lot of warrants. I don't think they are tradeable.

Schwab charges $50 commission on foreign transactions. First I knew of that.

Are part of the problem convertibles?

Our downfall has nothing to do with what the market does. The market went thru the roof for the last 3 years and BABYF went down the drain all along.
OUR PROBLEM IS OUR DUMB CEO!

JP, crap shot here. Know the extent of loss if Baby goes belly up and take a shot.

Stocks market this Sept was the worst in 23 years.

(CAD) Jun 2024 Y/Y
Revenue 2.63M
Net income -2.52M
And the boss keeps cutting expenses, adding shelves (inventories) and not doing any marketing investment. Hard to find a more incompetent CEO.

That could be except for ''surprise sales increase''. As for FDA approval (assuming it is still possible) it would change nothing unless our stubborn CEO also decide to invest in marketing.

If our CEO keep making a fool of herself, you may very well be right.

Harbor, perhaps! However we just might have (temporarily) bottomed out the last few days.
KIM prior to your prediction arriving at fruition, good things could happen: Buy out offer, FDA approval, Mgmt making bid to go private, surprise sales increase.

Its over gere. A RS or bankrupt in 6 months

And the woman stays silent, most likely in her lab working at developping a new product. How stupid can someone be !!!

I would rather buy at these prices than sell. BUY LOW and this is lowest.

Again, I don't own this obvious piece of junk. Never did. And pennyland patents never have real value.

Gee, a mix of almonds, buckwheat, and tapioca.

Maybe but i hope that someone will fet to our CEO and make her understand that she baddly needs help. Right now our market value is less than $10,000,000 or our yearly gross revenue. Even her may figure out that she is digging her own (and our) grave ???

Unless you believe that there must be a limit to the stupidity of the CEO. There is a lot of value in this company and the issue is not with the offering but with the way management doesn't talk to the market.
This being said, I agree that averaging down is generally quite a bad idea.